Bio-Rad Laboratories (NYSE:BIO) Price Target Increased to $350.00 by Analysts at Citigroup
Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price objective raised by Citigroup from $300.00 to $350.00 in a report issued on Friday morning, Benzinga reports. Citigroup currently has a neutral rating on the medical research company’s stock. A number of other equities analysts have also weighed in on the stock. UBS Group cut their […]
More Stories
Invesco Municipal Strategic Income ETF (BATS:IMSI) Announces Dividend Increase – $0.17 Per Share
Invesco Municipal Strategic Income ETF (BATS:IMSI – Get Free Report) declared a dividend on Friday, September 20th, NASDAQ reports. Stockholders...
Southern Cross Electrical Engineering Limited (ASX:SXE) Plans Dividend Increase – $0.05 Per Share
Southern Cross Electrical Engineering Limited (ASX:SXE – Get Free Report) announced a final dividend on Thursday, September 19th, MarketIndexAU reports....
Regency Centers (NASDAQ:REG) Updates FY 2024 Earnings Guidance
Regency Centers (NASDAQ:REG – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The...
Steel Dynamics (NASDAQ:STLD) Issues Q3 2024 Earnings Guidance
Steel Dynamics (NASDAQ:STLD – Get Free Report) updated its third quarter 2024 earnings guidance on Friday. The company provided EPS...
Corning (NYSE:GLW) Issues Q3 2024 Earnings Guidance
Corning (NYSE:GLW – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The...
Brokerages Set América Móvil, S.A.B. de C.V. (NYSE:AMX) PT at $21.39
Shares of América Móvil, S.A.B. de C.V. (NYSE:AMX – Get Free Report) have been assigned an average recommendation of “Moderate...